

ACCEPTED MANUSCRIPT

## Automated detection of breast cancer in resected specimens with fluorescence lifetime imaging

To cite this article before publication: Jennifer E Phipps *et al* 2017 *Phys. Med. Biol.* in press <https://doi.org/10.1088/1361-6560/aa983a>

### Manuscript version: Accepted Manuscript

Accepted Manuscript is “the version of the article accepted for publication including all changes made as a result of the peer review process, and which may also include the addition to the article by IOP Publishing of a header, an article ID, a cover sheet and/or an ‘Accepted Manuscript’ watermark, but excluding any other editing, typesetting or other changes made by IOP Publishing and/or its licensors”

This Accepted Manuscript is © 2017 Institute of Physics and Engineering in Medicine.

During the embargo period (the 12 month period from the publication of the Version of Record of this article), the Accepted Manuscript is fully protected by copyright and cannot be reused or reposted elsewhere.

As the Version of Record of this article is going to be / has been published on a subscription basis, this Accepted Manuscript is available for reuse under a CC BY-NC-ND 3.0 licence after the 12 month embargo period.

After the embargo period, everyone is permitted to use copy and redistribute this article for non-commercial purposes only, provided that they adhere to all the terms of the licence <https://creativecommons.org/licenses/by-nc-nd/3.0>

Although reasonable endeavours have been taken to obtain all necessary permissions from third parties to include their copyrighted content within this article, their full citation and copyright line may not be present in this Accepted Manuscript version. Before using any content from this article, please refer to the Version of Record on IOPscience once published for full citation and copyright details, as permissions will likely be required. All third party content is fully copyright protected, unless specifically stated otherwise in the figure caption in the Version of Record.

View the [article online](#) for updates and enhancements.

1  
2  
3 **Automated detection of breast cancer in resected specimens with fluorescence lifetime**  
4  
5 **imaging**  
6  
7

8 Jennifer E. Phipps, PhD,<sup>1</sup> Dimitris Gorpas, PhD,<sup>1§</sup> Jakob Unger, PhD,<sup>1</sup> Morgan Darrow, MD,<sup>2</sup>  
9  
10 Richard J. Bold, MD,<sup>3</sup> Laura Marcu, PhD<sup>1</sup>  
11  
12

13  
14 <sup>1</sup>University of California, Davis, Biomedical Engineering Department, 1 Shields Ave, Davis CA  
15 95616 <sup>2</sup>University of California Davis Health System, Department of Pathology and Laboratory  
16  
17 Medicine, <sup>3</sup> University of California Davis Health System, Department of Surgery  
18  
19

20  
21  
22 <sup>§</sup>Current affiliation: Helmholtz Zentrum München, Institute of Biological and Medical Imaging  
23  
24  
25  
26  
27

28 Corresponding author: Laura Marcu, 451 Health Sciences Dr, GBSF 2303, Davis CA 95616,  
29  
30 lmarcu@ucdavis.edu, 1 (530) 752-0288  
31  
32

33  
34 Word count: 4,058  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Abstract**

Re-excision rates for breast cancer lumpectomy procedures are currently nearly 25% due to surgeons relying on inaccurate or incomplete methods of evaluating specimen margins. The objective of this study was to determine if cancer could be automatically detected in breast specimens from mastectomy and lumpectomy procedures by a classification algorithm that incorporated parameters derived from fluorescence lifetime imaging (FLIm). This study generated a database of co-registered histologic sections and FLIm data from breast cancer specimens (N=20) and a support vector machine (SVM) classification algorithm able to automatically detect cancerous, fibrous, and adipose breast tissue. Classification accuracies were greater than 97% for automated detection of cancerous, fibrous, and adipose tissue from breast cancer specimens. The classification worked equally well for specimens scanned by hand or with a mechanical stage, demonstrating that the system could be used during surgery or on excised specimens. The ability of this technique to simply discriminate between cancerous and normal breast tissue, in particular to distinguish fibrous breast tissue from tumor, which is notoriously challenging for optical techniques, leads to the conclusion that FLIm has great potential to assess breast cancer margins. Identification of positive margins before waiting for complete histologic analysis could significantly reduce breast cancer re-excision rates.

## Introduction

Recent statistics indicate that breast cancer is the leading cause of cancer-related death and the 2<sup>nd</sup> most diagnosed cancer for women in the United States and is the most common cancer in women worldwide (Fitzmaurice *et al.*, 2016). Currently, an American woman has a 1 in 9 chance of developing breast cancer during her lifetime (Fitzmaurice *et al.*, 2016). Breast-conserving surgery (lumpectomy) followed by radiation is the standard-of-care surgical intervention for early-stage cancer and is as effective as mastectomy in many cases (O'Kelly Priddy *et al.*, 2015). From a 2009 study, 37.9% of 1459 lumpectomy procedures resulted in positive margins (Morrow *et al.*, 2009) and 50% of reoperations due to positive margin findings did not find residual tumor (Azu *et al.*, 2010). Additionally, positive margins are correlated with a significant increase in ipsilateral breast tumor regional recurrence (Houssami *et al.*, 2014) and reoperation is associated with greater physical and emotional trauma to the patient, a higher incidence of complications, and poorer cosmetic outcomes (St John *et al.*, 2017). The most accurate methods to assess tumor margins are cytology and frozen sections, both of which require significant time and cost and thus are not commonly performed (St John *et al.*, 2017). A fast, cost-effective and accurate way to assess breast cancer margins intraoperatively or immediately following resection is in high demand.

Optical techniques provide a means to non-destructively probe tissue composition, making them safe for intraoperative use. Studies have been done to determine the capability of several optical techniques to potentially diagnose breast cancer specimens. This includes diffuse reflectance spectroscopy (DRS) (de Boer *et al.*, 2016; Brown *et al.*, 2010; Keller *et al.*, 2010), diffuse optical spectroscopy (DOS) (Nichols *et al.*, 2017), Raman spectroscopy (Kong *et al.*, 2014), fluorescence spectroscopy (Keller *et al.*, 2010), optical coherence tomography (OCT)

1  
2  
3 (Nguyen *et al.*, 2009; Zysk *et al.*, 2015; Erickson-Bhatt *et al.*, 2015), optical coherence micro-  
4  
5 elastography (Allen *et al.*, 2016), autofluorescence lifetime microscopy (Sharma *et al.*, 2012),  
6  
7 and photoacoustic microscopy (Wong *et al.*, 2017). Moreover, few of these have been used to  
8  
9 assess margins intraoperatively (i.e. DRS, DOS, and OCT), but none have been widely adopted  
10  
11 into regular clinical practice due to inherent limitations. For example, while fibrous tissue will  
12  
13 appear more uniform with OCT than tumor (Erickson-Bhatt *et al.*, 2015), OCT still has limited  
14  
15 ability to distinguish between cancerous and fibrous breast tissue due to potentially similar  
16  
17 structural features of these tissue types (Nguyen *et al.*, 2009). Also, while a careful study of  
18  
19 normal and cancerous breast tissue has been performed with DRS (Kennedy *et al.*, 2016), an  
20  
21 automated method to distinguish cancer based on DRS measurements has not been  
22  
23 demonstrated. Furthermore, a recent meta-analysis of intraoperative margin assessment  
24  
25 techniques showed that optical techniques will need to be both improved in accuracy for cancer  
26  
27 detection and more convenient and cost-effective before they will be accepted by the wider  
28  
29 clinical community (St John *et al.*, 2017). Additionally, new work is being done to achieve  
30  
31 pathology-like images through staining resected samples and performing optical imaging; for  
32  
33 instance light-sheet microscopy (Glaser *et al.*, 2017) and fluorescence imaging (Davis *et al.*,  
34  
35 2013). These show great promise for identifying tumor margins, but in comparison to other  
36  
37 optical techniques, have the drawback of requiring tissue staining prior to imaging.  
38  
39  
40  
41  
42  
43  
44  
45

46  
47 Taking advantage of the autofluorescence properties of breast tissue, earlier studies have  
48  
49 shown that fluorescence intensity-based spectroscopy techniques enable detection of breast  
50  
51 cancer with good sensitivity and specificity (85% and 96%, respectively) (Keller *et al.*, 2010).  
52  
53 Time-resolved (lifetime) fluorescence spectroscopy techniques can improve these statistics by  
54  
55 providing an additional means to analyze tissue autofluorescence by separating tissue  
56  
57  
58  
59  
60

1  
2  
3 fluorophores with overlapping fluorescence intensity parameters but distinct fluorescence  
4  
5 lifetimes. Such techniques, however, have only been sparsely explored for diagnosis of breast  
6  
7 cancer (Sharma *et al.*, 2012; Gorpas *et al.*, 2015). Endogenous fluorophores distinguishable by  
8  
9 fluorescence lifetime techniques and relevant to breast cancer detection include adipose tissue,  
10  
11 collagen fibers, nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide  
12  
13 (FAD).  
14  
15

16  
17  
18 While the potential diagnostic capabilities of fluorescence lifetime techniques have been  
19  
20 demonstrated in pre-clinical studies, many challenges exist for clinical translation including  
21  
22 complex instrumentation, time-consuming data analysis, and a lack of ability for clinicians to  
23  
24 simply obtain fluorescence lifetime data and quickly display conclusive diagnostic information.  
25  
26 Recent advances in fluorescence lifetime imaging (FLIm) instrumentation with a fast and  
27  
28 compact scanning fiber-based system (Yankelevich *et al.*, 2014; Ma *et al.*, 2015) enable  
29  
30 acquisition of FLIm images either during surgery or on excised specimens, in real-time as the  
31  
32 FLIm fiber optic is scanned over the tissue via hand scanning or with an automated mechanical  
33  
34 stage. The system is housed in a compact cart that can be transported easily to operating or  
35  
36 pathology rooms. The goals of this study were to demonstrate: 1) the ability of this compact  
37  
38 system to acquire data from breast specimens in scenarios that mimic the intraoperative setting,  
39  
40 which would require hand scanning during surgery or a mechanical stage for scanning excised  
41  
42 specimens; and 2) the accuracy of a classification algorithm that employs optical parameters  
43  
44 derived from FLIm measurements to automatically output diagnostic information about breast  
45  
46 specimens as independently validated with histology. Our findings show that this FLIm  
47  
48 technique may be a contender for reducing breast cancer re-excision rates due to its ability to  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 accurately and quickly distinguish cancer from normal tissue in a manner that could identify  
4  
5 positive margins intraoperatively either during surgery or on resected tissue specimens.  
6  
7

## 8 9 **Methods**

10  
11 **Breast specimens.** Tissue specimens (N=20) from breast cancer patients (N=14 total: N=4  
12  
13 lumpectomies, N=10 mastectomies) were imaged within an hour of resection. Multiple pieces of  
14  
15 tissue were imaged from N=5 of the total patients, which is why there are N=20 specimens, but  
16  
17 only N=14 patients. All patients provided informed consent. See **table 1** for a summary of  
18  
19 patient information. The University of California Davis Health System Institutional Review  
20  
21 Board approved this study.  
22  
23  
24

25  
26 **Imaging protocol.** The tissue was assessed by a pathologist and regions thought to contain  
27  
28 tumor were cut into sizes that could be fit in a single tissue processing cassette (~20 mm x 20  
29  
30 mm x 4-5 mm), with slight irregularities in the overall shape to assist with later co-registration  
31  
32 between histology and FLIm data. Ink was used to mark the edges of the specimen and to assist  
33  
34 with co-registration. The samples were placed on an imaging stage and scanned with the FLIm  
35  
36 fiber optic either manually by hand or automatically by a mechanical stage to mimic how this  
37  
38 system could be used either during surgery or following surgery on excised tissue specimens,  
39  
40 respectively. High-resolution white-light images as well as the video stream of the scanning were  
41  
42 also acquired (see **videos 1** and **2**). The fluorescence lifetime values derived from FLIm  
43  
44 measurements were augmented with the video stream of the tissue for visualization during  
45  
46 imaging and saved for further analysis. The FLIm system and the process to augment the video  
47  
48 stream are described below. Following imaging, specimens were placed in formalin and  
49  
50 processed routinely for histologic analysis.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Histology.** Tissue sections were cut parallel to the imaging plane, thus each histologic section  
4 corresponded to one entire field of view of a FLIm dataset. The sections were stained with  
5 hematoxylin and eosin (H&E) and scanned with an Aperio Digital Pathology Slide Scanner  
6 (Leica Biosystems). The pathologist (M.D.) traced regions of fibrous tissue, normal ducts and  
7 lobules, fat, invasive cancer and ductal carcinoma in situ (DCIS) using Aperio ImageScope  
8 (Leica Biosystems). The FLIm interrogation depth is  $\sim 300 \mu\text{m}$  (Ghosh *et al.*, 2001; Palmer *et al.*,  
9 2006) and the depth of a single histologic tissue section was  $4 \mu\text{m}$ . To determine how much the  
10 breast tissue composition changed within the  $300 \mu\text{m}$  depth, in  $N=2$  cases multiple  $4 \mu\text{m}$  sections  
11 were cut within the  $300 \mu\text{m}$  imaged volume. Matlab (The Mathworks, Inc.) software was used  
12 for selecting regions of interest in the FLIm images and for image analysis.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27 **Region of Interest Selection.** Pathologist tracings from the histology sections were exported  
28 from the Aperio software and co-registered with the white light images of the breast tissue, using  
29 the shape of the tissue sections and ink as fiducial markers. Regions of interest (ROIs) were  
30 drawn within the tracings, with a  $0.5 \text{ mm}$  margin to account for errors in co-registration. See  
31 **fig1.**  
32  
33  
34  
35  
36  
37  
38  
39

40 **FLIm system.** The imaging setup consisted of a prototype point scanning FLIm instrumentation  
41 and an aiming beam module (Gorpas *et al.*, 2016b). The aiming beam detection scheme allowed  
42 the FLIm images to be reconstructed from the scanning point measurements in real time. The  
43 FLIm system is based on a pulse-sampling fluorescence lifetime measurement technique and has  
44 been described previously (Yankelevich *et al.*, 2014; Gorpas *et al.*, 2016b). Fluorescence  
45 excitation was produced with a micro Q-switched laser frequency tripled to  $355 \text{ nm}$  with a  $2$   
46 KHz repetition rate (Teem Photonics<sup>TM</sup>, France). The resulting fluorescence emission from the  
47 tissue specimens was sequentially spectrally resolved into four channels:  $390/40 \text{ nm}$  (channel 1),  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 466/40 nm (channel 2), 542/50 nm (channel 3), and 629/53 nm (channel 4) (Yankelevich *et al.*,  
4  
5  
6 2014). Each channel was connected to an optical fiber of varying length that allowed all 4 signals  
7  
8 generated from a single laser pulse to arrive sequentially at distinct time points at the detector, a  
9  
10 single microchannel plate photomultiplier tube (MCP-PMT, R3809U-50, Hamamatsu, 45 ps  
11  
12 FWHM). The signals were then increased by an RF amplifier (AM-1607-3000, 3 GHz  
13  
14 bandwidth, Miteq, USA) and temporally resolved (80 ps intervals) by a high sampling frequency  
15  
16 digitizer (PXIe-5185, National Instruments, 12.5 GS/s sampling rate). A continuous-wave solid  
17  
18 state laser (450 nm, 50 mW, World Star Tech, Canada) coupled into the second channel allowed  
19  
20 the aiming beam (power ~ 3 mW) to be projected onto the tissue in the same location as the  
21  
22 fluorescence excitation beam. An external camera (Point Grey Chameleon3 1.3 MP Color USB3  
23  
24 Vision with Fujinon HF9HA-1B 2/3" 9mm lens) recorded the entire specimen, including the  
25  
26 aiming beam, during the scanning procedure. The video images were converted to the HSV  
27  
28 color space and the blue aiming beam was segmented by thresholding the hue channel, providing  
29  
30 co-registration between the FLIm measurements and the video of the tissue. Once the location of  
31  
32 the aiming beam is determined, the FLIm data acquired from that location was augmented in real  
33  
34 time with the video display of the scanning procedure. Thus as the tissue was scanned, an image  
35  
36 of the FLIm data was reconstructed within the video stream of the tissue visualized on the FLIm  
37  
38 system computer monitor, creating an augmented view of the tissue overlaid with the FLIm  
39  
40 values. (Gorpas *et al.*, 2016a) This can be observed in **fig1**, **fig2** and **videos 1** and **2**.  
41  
42  
43  
44  
45  
46  
47  
48

49 **FLIm parameters.** Following the acquisition of the fluorescence decay signal, constrained least-  
50  
51 squares deconvolution based on the Laguerre expansion method was performed to determine the  
52  
53 fluorescence response of the tissue (Liu *et al.*, 2012). From the deconvolved fluorescence decay,  
54  
55 the average lifetimes and intensity ratios were derived. The average lifetime is the average  
56  
57  
58  
59  
60

1  
2  
3 amount of time a fluorophore spends in the excited state. The probability distribution of detected  
4 photons is obtained by normalizing the deconvolved fluorescence intensity decay. The average  
5 lifetime is then defined as the expected value of this distribution (Lakowicz, 1999). Intensity  
6 ratios were computed by taking the ratio of the fluorescence intensity at each channel divided by  
7 the sum of all four intensity channels.  
8  
9

10  
11  
12  
13  
14  
15  
16 **Statistics.** Support vector machines (SVM) with a RBF kernel (Chang and Lin, 2011) were used  
17 to classify FLIm data into three groups based on training from histology: adipose, fibrous and  
18 cancerous. The feature vector included average fluorescence lifetime from channels 1, 2, 3 and 4.  
19  
20  
21  
22  
23 Multiclass classification was realized through the “one-against-one” strategy (Hsu and Lin,  
24 2002). The cancerous regions included both invasive cancer and ductal carcinoma in situ.  
25  
26  
27  
28 Sensitivity, specificity, positive predictive value and negative predictive value were calculated  
29 with leave one out cross-validation. This involved sequentially leaving data from a single patient  
30 out of the training set, then testing the classification accuracy on that single patient for all  
31 patients. Since multiple specimens were imaged for N=5 patients, the leave one out cross-  
32 validation was performed per patient rather than per specimen. The leave one out cross-  
33 validation was performed twice, first with the numbers of pixels per group in the training set  
34 imbalanced and next with balanced numbers between groups. The numbers of pixels per group  
35 were forced to be balanced by randomly sampling by randomly sampling 31 pixels per group  
36 from each sample, the size of the smallest group per sample in the dataset (Chawla *et al.*, 2004).  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49 Average fluorescence lifetime values are presented as mean  $\pm$  standard deviation. To remove  
50 dependence between pixels, the median from each patient from each group was used as the  
51 outcome variable and a non-parametric Kruskal-Wallis test was performed to determine  
52 statistical significance between groups because the data was not normally distributed, as  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 determined with a Kolmogorov-Smirnov test. Post-hoc Mann–Whitney U-tests were performed  
4 to determine the p values for the outcome variables (median values) from each set of groups.  
5  
6 Image analysis, classification and statistical analyses were performed using MATLAB (The  
7  
8 Mathworks, Inc.). The classification algorithm and results (**Tables 2** and **3**) only included data  
9  
10 from a 0.5 mm border within the pathologist tracings of the histology. Data that was scanned by  
11  
12 hand was thresholded to remove artifacts that occur at the edges of the specimen (see **fig2**). The  
13  
14 classification algorithm was validated for the ROIs carefully co-registered with histology,  
15  
16 however classification was also performed for all pixels acquired for each specimen (**fig1C** and  
17  
18 **fig2D**).

## 24 25 **Results**

26  
27  
28 See **videos 1** and **2** for a demonstration of data being recorded and simultaneously  
29  
30 displayed on the video feed of samples imaged by hand and by the automated stage, respectively.  
31  
32 Regions of interest were selected from each of the specimens for a total of N=14,688 pixels  
33  
34 associated with fibrous tissue, N=67,465 associated with cancerous tissue and N=24,311  
35  
36 associated with adipose tissue. Average spatial resolution was approximately 60 points/mm<sup>2</sup>.  
37  
38

39  
40 **Average fluorescence lifetime.** The mean average lifetime values for each spectral detection  
41  
42 channel from within 0.5 mm borders of the pathologist tracings on the FLIm images co-  
43  
44 registered with histology (**fig3**) were computed. Average fluorescence lifetime from detection  
45  
46 channel 1 identifies fibrous regions with the highest values and adipose with lowest values. For  
47  
48 spectral channels 2, 3 and 4 the lifetimes from adipose are highest, fibrous in the middle and  
49  
50 cancer the lowest. **Fig1** and **fig2** demonstrate representative examples. The Kruskal-Wallis test  
51  
52 found that the fluorescence lifetimes were significantly different (p<0.001). Additionally, the  
53  
54 rank sum test found that the differences in all detection channels between all groups were  
55  
56  
57  
58  
59  
60

1  
2  
3 statistically significantly different ( $p < 0.001$ ) for all groups excluding fibrous compared to cancer  
4  
5 in channel 1 ( $p = 0.64$ ).  
6  
7

8  
9 **Classification results.** The sensitivity, specificity, positive and negative predictive values for  
10  
11 discriminating between adipose, cancerous and fibrous tissue are summarized in **table 2**. When  
12  
13 groups were forced to be balanced by randomly sampling  $N=31$  points per group per sample, the  
14  
15 results were slightly different, as summarized in **table 3**. The SVMs for lifetime values of each  
16  
17 set of groups (adipose vs. fibrous, adipose vs. cancer, fibrous vs. cancer) and scatter plots of the  
18  
19 fluorescence lifetime data can be seen in **fig4**.  
20  
21  
22

23  
24 **Histology co-registration.** The pathologist (M.D.) compared histology sections from 3 levels  
25  
26 within the  $300\ \mu\text{m}$  imaged region and found that the breast tissue did not vary significantly in  
27  
28 these  $N=2$  samples to warrant cutting multiple levels from each sample. Thus for the remaining  
29  
30  $N=18$  samples, the first complete section from the paraffin block was used to interpret the results  
31  
32 of the entire  $300\ \mu\text{m}$  imaged volume.  
33  
34  
35

## 36 Discussion

37  
38  
39 This study demonstrates that spectroscopic features derived from FLIm images are  
40  
41 capable of being used to distinguish between adipose, fibrous and cancerous regions in breast  
42  
43 specimens from women undergoing lumpectomies and mastectomies. The system is compatible  
44  
45 with intraoperative applications. It allows for hand scanning the surgical bed with a fiber optic or  
46  
47 automatic scanning of resected *ex vivo* tissue specimens on a mechanical stage. Fluorescence  
48  
49 lifetime information is displayed as the scanning is conducted and a classification algorithm was  
50  
51 developed to automate distinction between these three tissue types. The classification algorithm  
52  
53 worked equally well for data acquired via hand scanning and automated stage scanning. The  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 classification is able to be performed fast enough that it could be implemented in real time as the  
4 measurements are acquired, which shows the potential of this technology as an intraoperative  
5  
6  
7  
8 tool either during surgery or on resected specimens for tumor margins assessment.  
9

10  
11 The ability of this FLIm technique to distinguish between breast tissue types is due to the  
12 endogenous fluorescence of the fluorophores that comprise those tissues, specifically: fat cells,  
13 collagen fibers, NADH and FAD. Adipose tissue is connective tissue predominantly composed  
14 of fat cells. From our histologic co-registration, we see that the adipose tissue tends to fluoresce  
15 with long lifetimes at the longer wavelengths detected in spectral channels 2, 3 and 4 of the  
16 FLIm apparatus (**fig3**), as is consistent with previous studies of adipose tissue fluorescence  
17 (Datta *et al.*, 2015; Swatland, 1987). Fibrous tissue is composed of bundles of collagen fibers,  
18 and fluoresces with a lifetime longer than cancer, but shorter than adipose tissue, based on our  
19 histologic co-registration (**fig3**). Importantly, this FLIm technique can clearly distinguish  
20 between fibrous and cancer, unlike some other optical techniques (**fig3, fig4B**). Cancer cells have  
21 altered NADH and FAD metabolism in comparison to normal tissue according to the Warburg  
22 theory (Druzhkova *et al.*, 2016). Free NADH and bound FAD have relatively short lifetimes and  
23 fluoresce predominantly in the wavelengths detected by channels 2, 3 and 4, which may explain  
24 the shorter lifetimes of cancerous breast tissue in these channels, though we cannot determine  
25 NADH and FAD presence with histologic methods (Skala *et al.*, 2007). While the trends in  
26 fluorescence lifetime detected in spectral channel 1 were also statistically significant, channels 2,  
27 3, and 4 exhibit the greatest amount of separation between groups.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51  
52 The margin of healthy tissue around the lumpectomy specimens necessary for negative  
53 margins has been controversial. As recently as 2013, standard of care required breast cancer  
54 margins to be 1-2 mm in depth, depending on the cancer type and surgeon. However, recent  
55  
56  
57  
58  
59  
60

1  
2  
3 studies demonstrated that a “no ink on tumor” margin for lumpectomy specimens leads to patient  
4  
5 outcomes equivalent to those from the previous 1-2 mm guideline (Moran *et al.*, 2014). The “no  
6  
7 ink on tumor” guideline defines negative cancer margins as occurring when there are no tumor  
8  
9 cells touching the ink used to mark the entire lumpectomy specimen. The 355 nm FLIm imaging  
10  
11 system excitation light penetrates approximately 300 microns into the breast tissue and thus will  
12  
13 identify cancer cells right at the surface, in the same region as the “no ink on tumor” guideline  
14  
15 suggests. Thus this FLIm system can probe the same region of tissue important for determining  
16  
17 margin status based on current clinical guidelines.  
18  
19  
20  
21  
22

23 The scanning speed of the FLIm system can be varied based on parameters input to the  
24  
25 mechanical stage or by the person performing the hand scanning. Two representative speeds can  
26  
27 be seen in **videos 1 and 2**. While mechanical stage scanning is slower in this case, the resolution  
28  
29 is higher in comparison to the hand scanning, which is faster but with lower resolution. Thus we  
30  
31 anticipate hand scanning would be performed to identify positive margins in the operating room  
32  
33 or frozen section room immediately following tissue resection and mechanical stage scanning  
34  
35 would be reserved for cases where higher resolution is necessary, such as if in the future it is  
36  
37 determined that FLIm can be used to study specifics of cancer type as well as positive or  
38  
39 negative margins. However, the limiting factor of the slow mechanical stage scanning was the  
40  
41 stage itself; with an improved stage, the FLIm system would be capable of operating at much  
42  
43 faster speeds that could allow for the higher resolution scans to be obtained from both the  
44  
45 operating room and frozen section room.  
46  
47  
48  
49  
50  
51

52 We acknowledge that a limitation to this study is the fact that only small regions of tissue  
53  
54 within the traced outlines of each tissue type were included in the classification analysis (see  
55  
56 **fig1F** and **fig2A**). This study design was used to reduce errors caused by co-registration between  
57  
58  
59  
60

1  
2  
3 the FLIm data and histology that are predominantly caused by: 1) tissue shrinkage and warping  
4 during histological processing, 2) the use of a single 4  $\mu\text{m}$  histology section to represent the  
5 entire imaged volume and 3) the use of a computer mouse to trace the relevant tissue types,  
6 which does not allow for very detailed lines to be drawn with the Aperio software. Our work  
7 currently does not take into account the ways that multiple light scattering events may affect  
8 fluorescence lifetime, however our excitation-collection geometry and fast temporal resolution  
9 reduce the possibility that scattering affects our fluorescence lifetime measurements. In the  
10 future, this could be thoroughly studied with a technique such as lifetime tomography (Gao *et al.*,  
11 2008; Cai *et al.*, 2016). Additionally, while we hypothesize that NADH and FAD allow us to  
12 distinguish cancerous from fibrous and adipose tissue based on known fluorescence lifetime  
13 properties of these molecules, we can't verify this without chemical analysis. Since our  
14 specimens are *ex vivo*, this also only allows us to assess the state that the NADH and FAD were  
15 in following tissue resection in comparison to the true state they existed in in living tissue. We  
16 also acknowledge that these results will need to be validated in a larger cohort, and we aim to  
17 move to entire lumpectomy specimens rather than sections of lumpectomy and mastectomy  
18 specimens for this work. A larger cohort will also enable the study of whether DCIS and invasive  
19 cancer can be distinguished using this technique. In the current study, nevertheless, cancerous  
20 tissue, regardless of cancer type, was discriminated from normal breast tissue (both fibrous and  
21 adipose).

22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49 In conclusion, normal fibrous and adipose tissue was able to be distinguished from  
50 cancerous breast tissue with accuracy > 97% with a classification algorithm designed using  
51 FLIm derived parameters. The FLIm measurements can be acquired within minutes either by  
52 hand or automated scanning of a fiber optic, without the need for contrast agents or dyes and  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 without damaging tissue. Additionally, the FLIm signal is generated from the region of breast  
4  
5 specimens appropriate for current guidelines for determining tumor margin status. All combined,  
6  
7 these results indicate that the current technique has great potential for further application in the  
8  
9 field of surgical breast oncology to reduce rates of re-excision by determining tumor margin  
10  
11 status intraoperatively either during surgery or on resected tissue specimens.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## References

- Allen W M, Chin L, Wijesinghe P, Kirk R W, Latham B, Sampson D D, Saunders C M and Kennedy B F 2016 Wide-field optical coherence micro-elastography for intraoperative assessment of human breast cancer margins *Biomed Opt Express* **7** 4139-53
- Azu M, Abrahamse P, Katz S J, Jagsi R and Morrow M 2010 What is an adequate margin for breast-conserving surgery? Surgeon attitudes and correlates *Ann Surg Oncol* **17** 558-63
- Brown J Q, Bydlon T M, Richards L M, Yu B, Kennedy S A, Geradts J, Wilke L G, Junker M, Gallagher J, Barry W and Ramanujam N 2010 Optical assessment of tumor resection margins in the breast *IEEE J Sel Top Quantum Electron* **16** 530-44
- Cai C, Cai W, Cheng J, Yang Y and Luo J 2016 Self-guided reconstruction for time-domain fluorescence molecular lifetime tomography *J Biomed Opt* **21** 126012
- Chang C C and Lin C J 2011 LIBSVM: A Library for Support Vector Machines *Acm T Intel Syst Tec* **2**
- Chawla N V, Japkowicz N and Kotcz A 2004 Editorial: special issue on learning from imbalanced data sets *SIGKDD Explor. Newsl.* **6** 1-6
- Datta R, Alfonso-Garcia A, Cinco R and Gratton E 2015 Fluorescence lifetime imaging of endogenous biomarker of oxidative stress *Sci Rep-Uk* **5**
- Davis S C, Gibbs S L, Gunn J R and Pogue B W 2013 Topical dual-stain difference imaging for rapid intra-operative tumor identification in fresh specimens *Opt Lett* **38** 5184-7
- de Boer L L, Hendriks B H W, van Duijnhoven F, Peeters-Baas M J T F D V, Van de Vijver K, Loo C E, Jozwiak K, Sterenborg H J C M and Ruers T J M 2016 Using DRS during breast conserving surgery: identifying robust optical parameters and influence of inter-patient variation *Biomedical Optics Express* **7** 5188-200

1  
2  
3 Druzhkova I N, Shirmanova M V, Lukina M M, Dudenkova V V, Mishina N M and Zagaynova  
4  
5 E V 2016 The metabolic interaction of cancer cells and fibroblasts - coupling between  
6  
7 NAD(P)H and FAD, intracellular pH and hydrogen peroxide *Cell Cycle* **15** 1257-66  
8  
9  
10 Erickson-Bhatt S J, Nolan R M, Shemonski N D, Adie S G, Putney J, Darga D, McCormick D T,  
11  
12 Cittadine A J, Zysk A M, Marjanovic M, Chaney E J, Monroy G L, South F A, Cradock  
13  
14 K A, Liu Z G, Sundaram M, Ray P S and Boppart S A 2015 Real-time Imaging of the  
15  
16 Resection Bed Using a Handheld Probe to Reduce Incidence of Microscopic Positive  
17  
18 Margins in Cancer Surgery *Cancer Res* **75** 3706-12  
19  
20  
21  
22 Fitzmaurice C, Allen C, Barber R M, Barregard L, Bhutta Z A, Brenner H, Dicker D J, Chimed-  
23  
24 Orchir O, Dandona R, Dandona L, Fleming T, Forouzanfar M H, Hancock J, Hay R J,  
25  
26 Hunter-Merrill R, Huynh C, Hosgood H D, Johnson C O, Jonas J B, Khubchandani J,  
27  
28 Kumar G A, Kutz M, Lan Q, Larson H J, Liang X, Lim S S, Lopez A D, MacIntyre M F,  
29  
30 Marczak L, Marquez N, Mokdad A H, Pinho C, Pourmalek F, Salomon J A, Sanabria J  
31  
32 R, Sandar L, Sartorius B, Schwartz S M, Shackelford K A, Shibuya K, Stanaway J,  
33  
34 Steiner C, Sun J, Takahashi K, Vollset S E, Vos T, Wagner J A, Wang H, Westerman R,  
35  
36 Zeeb H, Zoeckler L, Abd-Allah F, Ahmed M B, Alabed S, Alam N K, Aldhahri S F,  
37  
38 Alem G, Alemayohu M A, Ali R, Al-Raddadi R, Amare A, Amoako Y, Artaman A,  
39  
40 Asayesh H, Atnafu N, Awasthi A, Saleem H B, Barac A, Bedi N, Bensenor I, Berhane A,  
41  
42 Bernabe E, Betsu B, Binagwaho A, Boneya D, Campos-Nonato I, Castaneda-Orjuela C,  
43  
44 Catala-Lopez F, Chiang P, Chibueze C, Chittheer A, Choi J Y, Cowie B, Damtew S, das  
45  
46 Neves J, Dey S, Dharmaratne S, Dhillon P, Ding E, Driscoll T, Ekwueme D, Endries A  
47  
48 Y, Farvid M, Farzadfar F, Fernandes J, Fischer F, TT G H, Gebru A, Gopalani S, Hailu  
49  
50 A, Horino M, Horita N, Hussein A, Huybrechts I, Inoue M, Islami F, Jakovljevic M,  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Phipps--18

James S, Javanbakht M, Jee S H, Kasaeian A, Kedir M S, Khader Y S, Khang Y H, Kim D, Leigh J, Linn S, Lunevicius R, El Razek H M, Malekzadeh R, Malta D C, Marcenes W, Markos D, Melaku Y A, Meles K G, Mendoza W, Mengiste D T, Meretoja T J, Miller T R, Mohammad K A, Mohammadi A, Mohammed S, Moradi-Lakeh M, Nagel G, Nand D, Le Nguyen Q, Nolte S, Ogbo F A, Oladimeji K E, Oren E, Pa M, Park E K, Pereira D M, Plass D, Qorbani M, Radfar A, Rafay A, Rahman M, Rana S M, Soreide K, Satpathy M, Sawhney M, Sepanlou S G, Shaikh M A, She J, Shiue I, Shore H R, Shrimme M G, So S, Soneji S, Stathopoulou V, Stroumpoulis K, Sufiyan M B, Sykes B L, Tabares-Seisdedos R, Tadese F, Tedla B A, Tessema G A, Thakur J S, Tran B X, Ukwaja K N, Uzochukwu B S, Vlassov V V, Weiderpass E, Wubshet Terefe M, Yebyo H G, Yimam H H, Yonemoto N, Younis M Z, Yu C, Zaidi Z, Zaki M E, Zenebe Z M, Murray C J and Naghavi M 2016 Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study

*JAMA oncology*

Gao F, Zhao H, Zhang L, Tanikawa Y, Marjono A and Yamada Y 2008 A self-normalized, full time-resolved method for fluorescence diffuse optical tomography *Opt Express* **16**

13104-21

Ghosh N, Mohanty S K, Majumder S K and Gupta P K 2001 Measurement of optical transport properties of normal and malignant human breast tissue *Appl Opt* **40** 176-84

Glaser A K, Reder N P, Chen Y, McCarty E F, Yin C, Wei L, Wang Y, True L D and Liu J T C 2017 Light-sheet microscopy for slide-free non-destructive pathology of large clinical specimens **1** 0084

- 1  
2  
3 Gorpas D, Fatakdawala H, Zhang Y H, Bold R and Marcu L 2015 Fluorescence lifetime  
4 spectroscopy for breast cancer margins assessment *Proc Spie* **9318**  
5  
6  
7  
8 Gorpas D, Ma D, Bec J, Yankelevich D and Marcu L 2016a Real-Time Visualization of Tissue  
9 Surface Biochemical Features Derived from Fluorescence Lifetime Measurements *IEEE*  
10 *T Med Imaging* doi: 10.1109/TMI.2016.2530621  
11  
12  
13  
14 Gorpas D, Ma D, Bec J, Yankelevich D R and Marcu L 2016b Real-Time Visualization of  
15 Tissue Surface Biochemical Features Derived From Fluorescence Lifetime  
16 Measurements *IEEE Trans Med Imaging* **35** 1802-11  
17  
18  
19  
20  
21  
22 Houssami N, Macaskill P, Marinovich M L and Morrow M 2014 The association of surgical  
23 margins and local recurrence in women with early-stage invasive breast cancer treated  
24 with breast-conserving therapy: a meta-analysis *Ann Surg Oncol* **21** 717-30  
25  
26  
27  
28  
29  
30 Hsu C W and Lin C J 2002 A comparison of methods for multiclass support vector machines  
31 *Ieee T Neural Networ* **13** 415-25  
32  
33  
34 Keller M D, Majumder S K, Kelley M C, Meszoely I M, Boulos F I, Olivares G M and  
35 Mahadevan-Jansen A 2010 Autofluorescence and Diffuse Reflectance Spectroscopy and  
36 Spectral Imaging for Breast Surgical Margin Analysis *Laser Surg Med* **42** 15-23  
37  
38  
39  
40  
41 Kennedy S, Caldwell M, Bydlon T, Mulvey C, Mueller J, Wilke L, Barry W, Ramanujam N and  
42 Geradts J 2016 Correlation of breast tissue histology and optical signatures to improve  
43 margin assessment techniques *J Biomed Opt* **21** 66014  
44  
45  
46  
47  
48 Kong K, Zaabar F, Rakha E, Ellis I, Koloydenko A and Notingher I 2014 Towards intra-  
49 operative diagnosis of tumours during breast conserving surgery by selective-sampling  
50 Raman micro-spectroscopy *Physics in Medicine and Biology* **59** 6141-52  
51  
52  
53  
54  
55  
56 Lakowicz J R 1999 *Principles of Fluorescence Spectroscopy*: Springer, New York)  
57  
58  
59  
60

- 1  
2  
3 Liu J, Sun Y, Qi J and Marcu L 2012 A novel method for fast and robust estimation of  
4  
5 fluorescence decay dynamics using constrained least-squares deconvolution with  
6  
7 Laguerre expansion *Phys Med Biol* **57** 843-65  
8  
9
- 10 Ma D, Bec J, Gorpas D, Yankelevich D and Marcu L 2015 Technique for real-time tissue  
11  
12 characterization based on scanning multispectral fluorescence lifetime spectroscopy (ms-  
13  
14 TRFS) *Biomed Opt Express* **6** 987-1002  
15  
16
- 17 Moran M S, Schnitt S J, Giuliano A E, Harris J R, Khan S A, Horton J, Klimberg S, Chavez-  
18  
19 MacGregor M, Freedman G, Houssami N, Johnson P L and Morrow M 2014 Society of  
20  
21 Surgical Oncology-American Society for Radiation Oncology consensus guideline on  
22  
23 margins for breast-conserving surgery with whole-breast irradiation in stages I and II  
24  
25 invasive breast cancer *Ann Surg Oncol* **21** 704-16  
26  
27
- 28  
29 Morrow M, Jagsi R, Alderman A K, Griggs J J, Hawley S T, Hamilton A S, Graff J J and Katz S  
30  
31 J 2009 Surgeon recommendations and receipt of mastectomy for treatment of breast  
32  
33 cancer *JAMA* **302** 1551-6  
34  
35
- 36  
37 Nguyen F T, Zysk A M, Chaney E J, Kotynek J G, Oliphant U J, Bellafiore F J, Rowland K M,  
38  
39 Johnson P A and Boppart S A 2009 Intraoperative evaluation of breast tumor margins  
40  
41 with optical coherence tomography *Cancer Res* **69** 8790-6  
42  
43
- 44 Nichols B S, Llopis A, Palmer G M, McCachren S S, 3rd, Senlik O, Miller D, Brooke M A,  
45  
46 Jokerst N M, Geradts J, Greenup R and Ramanujam N 2017 Miniature spectral imaging  
47  
48 device for wide-field quantitative functional imaging of the morphological landscape of  
49  
50 breast tumor margins *J Biomed Opt* **22** 26007  
51  
52
- 53 O'Kelly Priddy C M, Forte V A and Lang J E 2015 The importance of surgical margins in breast  
54  
55 cancer *J Surg Oncol*  
56  
57  
58  
59  
60

- 1  
2  
3 Palmer G M, Zhu C, Breslin T M, Xu F, Gilchrist K W and Ramanujam N 2006 Monte Carlo-  
4 based inverse model for calculating tissue optical properties. Part II: Application to breast  
5 cancer diagnosis *Appl Opt* **45** 1072-8  
6  
7  
8  
9  
10 Sharma V, Shivalingaiah S, Peng Y, Euhus D, Gryczynski Z and Liu H 2012 Auto-fluorescence  
11 lifetime and light reflectance spectroscopy for breast cancer diagnosis: potential tools for  
12 intraoperative margin detection *Biomed Opt Express* **3** 1825-40.  
13  
14  
15  
16  
17 Skala M C, Riching K M, Gendron-Fitzpatrick A, Eickhoff J, Eliceiri K W, White J G and  
18 Ramanujam N 2007 In vivo multiphoton microscopy of NADH and FAD redox states,  
19 fluorescence lifetimes, and cellular morphology in precancerous epithelia *P Natl Acad Sci*  
20 *USA* **104** 19494-9  
21  
22  
23  
24  
25  
26  
27 St John E R, Al-Khudairi R, Ashrafian H, Athanasiou T, Takats Z, Hadjiminias D J, Darzi A and  
28 Leff D R 2017 Diagnostic Accuracy of Intraoperative Techniques for Margin Assessment  
29 in Breast Cancer Surgery: A Meta-analysis *Ann Surg* **265** 300-10  
30  
31  
32  
33  
34 Swatland H J 1987 Autofluorescence of Adipose-Tissue Measured with Fiber Optics *Meat Sci* **19**  
35 277-84  
36  
37  
38  
39 Wong T T W, Zhang R, Hai P, Zhang C, Pleitez M A, Aft R L, Novack D V and Wang L V 2017  
40 Fast label-free multilayered histology-like imaging of human breast cancer by  
41 photoacoustic microscopy *Sci Adv* **3** e1602168  
42  
43  
44  
45  
46 Yankelevich D R, Ma D, Liu J, Sun Y, Sun Y, Bec J, Elson D S and Marcu L 2014 Design and  
47 evaluation of a device for fast multispectral time-resolved fluorescence spectroscopy and  
48 imaging *Rev Sci Instrum* **85** 034303  
49  
50  
51  
52  
53 Zysk A M, Chen K, Gabrielson E, Tafra L, Gonzalez E A M, Canner J K, Schneider E B,  
54 Cittadine A J, Carney P S, Boppart S A, Tsuchiya K, Sawyer K and Jacobs L K 2015  
55  
56  
57  
58  
59  
60

Phipps--22

1  
2  
3 Intraoperative Assessment of Final Margins with a Handheld Optical Imaging Probe  
4  
5  
6 During Breast-Conserving Surgery May Reduce the Reoperation Rate: Results of a  
7  
8  
9 Multicenter Study *Annals of Surgical Oncology* **22** 3356-62  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Accepted Manuscript

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Tables

**Table 1.** Demographic and tumor characteristics of N=14 patients in this study.

Characteristic		Number (%)
Age	<50	3 (21)
	>50	9 (64)
	Unknown	2 (14)
Race	White, not hispanic or latino	12 (86)
	Unknown	2 (14)
Body mass index, kg/m <sup>2</sup>	Normal (<25)	5 (36)
	Overweight, 25-30	5 (36)
	Obese, ≥30	2 (14)
	Unknown	2 (14)
Menopausal status	Premenopausal	4 (29)
	Postmenopausal	10 (71)
	Unknown	2 (14)
Radiotherapy	No radiotherapy	8 (57)
	Radiotherapy	2 (14)
	Unknown	4 (29)
Hormone therapy	No	7 (50)
	Yes	4 (29)
	Unknown	3 (21)
Type of surgery	Lumpectomy	3 (21)
	Mastectomy	9 (64)
	Unknown	2 (14)
Receptor status	Negative	2 (14)
	Positive	8 (57)
	Unknown	4 (29)
Cancer stage	DCIS	3 (21)
	Invasive	9 (64)
	Unknown	2 (14)



**Table 2.** Results from leave-one-out cross validation with a Gaussian SVM (numbers of pixels per group imbalanced).

	Accuracy <sup>a</sup>	PPV <sup>a</sup>	Sensitivity analysis			Specificity analysis		
			SE <sup>a</sup>	No. TP	FN	SP <sup>a</sup>	No. TN	FP
cancer	99.0 (99.0- 99.1)	98.5 (98.4- 98.5)	100.0 (100.0- 100.0)	70555	1	97.4 (97.3- 97.5)	40819	1093
adipose	99.3 (99.3- 99.4)	99.9 (99.9- 100.0)	97.2 (97.1- 97.3)	25250	723	100.0 (100.0- 100.0)	86479	16
fibrous	99.7 (99.6- 99.7)	100.0 (100.0- 100.0)	97.6 (97.5- 97.7)	15552	387	100.0 (100.0- 100.0)	96527	2

Abbreviations: PPV, positive predictive value; SE, sensitivity; TP, true positive; FN, false negative; SP, specificity; TN, true negatives; FP, false positives.

<sup>a</sup>Value expressed as: % (95% CI)

Accepted Manuscript

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 3.** Results from leave-one-out cross validation with a Gaussian SVM (numbers of pixels per group balanced with 31 pixels per group from each sample).

	Sensitivity analysis			Specificity analysis			
	Accuracy <sup>a</sup>	PPV <sup>a</sup>	SE <sup>a</sup>	No. TP	FN	No. TN	FP
cancer	97.8 (96.9- 98.5)	93.1 (91.7- 94.4)	100.0 (99.7- 100.0)	434	0	96.9 (95.8- 97.7)	991 32
adipose	99.9 (99.6- 100.0)	100.0 (100.0- 100.0)	99.8 (99.4- 100.0)	526	1	100.0 (99.7- 100.0)	930 0
fibrous	97.7 (96.8- 98.4)	99.8 (99.3- 100.0)	93.5 (92.1- 94.7)	464	32	99.9 (99.5- 100.0)	960 1

Abbreviations: PPV, positive predictive value; SE, sensitivity; TP, true positive; FN, false negative; SP, specificity; TN, true negatives; FP, false positives.

<sup>a</sup>Value expressed as: % (95% CI)

Accepted Manuscript

**Figure legends.****Figure 1. Representative breast specimen automatically scanned on the mechanical stage.**

(A) White light image of a breast specimen scanned on a mechanical stage. (B) White light image augmented with FLIm data from spectral channel 2; (C) white light image augmented with classification results when this specimen was left out of the training set. (D) Corresponding H&E histology section. Cancer is outlined in red, adipose in blue and fibrous in green. Scale bar = 4 mm. (E) Zoomed in histology section from black dashed line in (D) with regions of interest included in the study shown with the filled-in shapes (red for cancer, blue for adipose, green for fibrous). Scale bar = 0.5 mm. These regions are overlaid with the breast specimen in (F).

**Figure 2. Representative breast specimen manually scanned by hand.** (A) H&E histology section from breast specimen overlaid with pathologist tracings and the regions of interest selected for the study (filled-in shapes). Scale bar = 4 mm. (B) The corresponding white light image of the breast specimen augmented with the regions of interest identified by the pathologist tracings. (C) White light image augmented with FLIm data from detection channel 2; (D) white light image augmented with the classification results when this specimen was left out of the training set.

**Figure 3. Average fluorescence lifetime from adipose, fibrous and cancerous breast tissue.**

This plot includes all data from the ROIs co-registered with histology and included in the classification algorithm. Fibrous: green circles, adipose: blue squares, and cancerous: red diamonds. Fluorescence lifetime (ns) can be seen to vary between the 3 breast tissue types.

$P < 0.001$  except for between fibrous and cancer in channel 1.

1  
2  
3 **Figure 4. SVM plots demonstrating discrimination between groups.** These plots demonstrate  
4 the SVMs that separate the three groups: (A) Adipose (blue) and fibrous (green), (B) fibrous and  
5 cancer (red), (C) adipose and cancer. The axes represent fluorescence lifetime (ns) in detection  
6 channels 1, 2 and 3.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Figures




Figure 1. Representative breast specimen automatically scanned on the mechanical stage.




Figure 2. Representative breast specimen manually scanned by hand.




Figure 3. Average fluorescence lifetime from adipose, fibrous and cancerous breast tissue.




Figure 4. SVM plots demonstrating discrimination between groups.